Abstracts tagged "cutaneous lupus erythematosus and race/ethnicity"

Abstract Number: 725 • 2018 ACR/ARHP Annual Meeting
Preliminary Population-Based Incidence and Prevalence Estimates of Primary Discoid Lupus and Cutaneous Lupus Erythematosus from the Manhattan Lupus Surveillance Program
Peter M. Izmirly¹, Jill P. Buyon², H. Michael Belmont³, Sara Sahl⁴, Isabella Wan⁵, Jane E. Salmon⁶, Anca Askanase⁷, Joan Bathon⁸, Laura Geraldino-Pardilla⁷, Yousaf Ali⁹, Ellen M. Ginzler¹⁰, Chaim Putterman¹¹, Caroline Gordon¹², Charles G. Helmick¹³ and Hilary Parton¹⁴, ¹NYU Langone Health, New York, NY, ²Medicine, New York University School of Medicine, New York, NY, ³Medicine, NYU Langone Health, New York, NY, ⁴Pediatrics, Harbor-University of California at Los Angeles Medical Center, Torrance, CA, ⁵Medicine/Rheumatology, New York University School of Medicine, New York, NY, ⁶Medicine/Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁸Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁹Rheumatology, Mount Sinai Medical Center, New York, NY, ¹⁰Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ¹¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ¹²Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ¹³Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ¹⁴Bureau of Epidemiology Services, New York City Department of Health and Mental Hygiene, Long Island City, NY
Background/Purpose: The extant epidemiologic data of primary discoid lupus erythematosus (DLE) and primary cutaneous lupus erythematosus (CLE) remains limited with few published estimates for the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].